These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 16115187

  • 1. Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients.
    Albaaj F, Hutchison AJ.
    Int J Clin Pract; 2005 Sep; 59(9):1091-6. PubMed ID: 16115187
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Improving phosphate-binder therapy as a way forward.
    Hutchison AJ.
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i19-24. PubMed ID: 15126650
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Improving outcomes in hyperphosphataemia.
    De Broe ME, D'Haese PC, Lanthanum Study Group.
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i14-8. PubMed ID: 15126649
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Lanthanum carbonate: a new phosphate binder.
    Behets GJ, Verberckmoes SC, D'Haese PC, De Broe ME.
    Curr Opin Nephrol Hypertens; 2004 Jul; 13(4):403-9. PubMed ID: 15199290
    [Abstract] [Full Text] [Related]

  • 11. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
    Finn WF, Joy MS, LAM-308 Study Group.
    Curr Med Res Opin; 2005 May; 21(5):657-64. PubMed ID: 15969865
    [Abstract] [Full Text] [Related]

  • 12. Hyperphosphataemia and treatment with sevelamer in haemodialysis patients.
    Cizman B.
    Nephrol Dial Transplant; 2003 Jul; 18 Suppl 5():v47-9. PubMed ID: 12817070
    [Abstract] [Full Text] [Related]

  • 13. Emerging drugs for hyperphosphatemia.
    Bellinghieri G, Santoro D, Savica V.
    Expert Opin Emerg Drugs; 2007 Sep; 12(3):355-65. PubMed ID: 17874966
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
    Joy MS, Finn WF, LAM-302 Study Group.
    Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461
    [Abstract] [Full Text] [Related]

  • 17. Lanthanum carbonate--a first line phosphate binder?
    de Freitas D, Donne RL, Hutchison AJ.
    Semin Dial; 2007 Jul; 20(4):325-8. PubMed ID: 17635822
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients.
    Almirall J, Lopez T, Vallve M, Ruiz A, Llibre J, Betriu A.
    Nephron Clin Pract; 2004 Jul; 97(1):c17-22. PubMed ID: 15153763
    [Abstract] [Full Text] [Related]

  • 19. A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis.
    Zhou T, Li H, Xie W, Lin Z.
    Afr Health Sci; 2018 Sep; 18(3):689-696. PubMed ID: 30603002
    [Abstract] [Full Text] [Related]

  • 20. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy.
    Wilson R, Zhang P, Smyth M, Pratt R.
    Curr Med Res Opin; 2009 Dec; 25(12):3021-8. PubMed ID: 19845495
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.